Armistice Capital, LLC Travere Therapeutics, Inc. Transaction History
Armistice Capital, LLC
- $6.56 Billion
- Q1 2025
A detailed history of Armistice Capital, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 8,872,000 shares of TVTX stock, worth $140 Million. This represents 2.42% of its overall portfolio holdings.
Number of Shares
8,872,000
Previous 7,358,000
20.58%
Holding current value
$140 Million
Previous $128 Million
24.04%
% of portfolio
2.42%
Previous 1.81%
Shares
16 transactions
Others Institutions Holding TVTX
# of Institutions
240Shares Held
101MCall Options Held
1.79MPut Options Held
555K-
Black Rock Inc. New York, NY7.64MShares$121 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$119 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$79.3 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$75.9 Million0.11% of portfolio
-
State Street Corp Boston, MA3.65MShares$57.7 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.02B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...